CompletedNot Applicable

SEntine Lymph Node in earLY Ovarian Cancer (SELLY)

Italy176 participantsStarted 2017-11-11

Plain-language summary

The present study aims at investigating the feasibility, the detection rate and the negative predictive value of sentinel node in predicting the presence or absence of lymph node metastasis in ovarian cancer patients

Who can participate

Age range18 Years – 80 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Epithelial ovarian cancer * Early stage disease limited to the ovary Exclusion Criteria: * Evidence of extraovarian disease * Allergy to the materials used

What they're measuring

Number of participants with procedure-related adverse events

Timeframe: 6 months

Detection rate

Timeframe: 24 months

Trial details

NCT IDNCT03563781

SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-07-29

View on ClinicalTrials.gov More Sentinel Lymph Node trials